Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has “approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.”

Even though the alleged benefit for adults 65 and older was never proven.

The move comes after the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in June that the “benefits” of Moderna’s experimental mRNA influenza vaccine “outweigh its risks.” [Read More]